0001493152-24-025813.txt : 20240701 0001493152-24-025813.hdr.sgml : 20240701 20240701163620 ACCESSION NUMBER: 0001493152-24-025813 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20240701 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240701 DATE AS OF CHANGE: 20240701 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Microbot Medical Inc. CENTRAL INDEX KEY: 0000883975 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 943078125 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-19871 FILM NUMBER: 241091176 BUSINESS ADDRESS: STREET 1: 25 RECREATION PARK DR SUITE 108 CITY: HINGHAM STATE: MA ZIP: 02043 BUSINESS PHONE: 908-938-5561 MAIL ADDRESS: STREET 1: 25 RECREATION PARK DR SUITE 108 CITY: HINGHAM STATE: MA ZIP: 02043 FORMER COMPANY: FORMER CONFORMED NAME: STEMCELLS INC DATE OF NAME CHANGE: 20000524 FORMER COMPANY: FORMER CONFORMED NAME: CYTOTHERAPEUTICS INC/DE DATE OF NAME CHANGE: 19930328 8-K 1 form8-k.htm
false 0000883975 0000883975 2024-07-01 2024-07-01 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): July 1, 2024

 

MICROBOT MEDICAL INC.

(Exact name of registrant as specified in its charter)

 

Delaware   000-19871   94-3078125

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

 

288 Grove Street, Suite 388

Braintree, MA 02184

(Address of Principal Executive Offices) (Zip Code)

 

Registrant’s telephone number, including area code: (781) 875-3605

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
   
Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, $0.01 par value   MBOT   NASDAQ Capital Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

 

Emerging Growth Company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 
 

 

Item 1.01 Entry into a Material Definitive Agreement.

 

On November 17, 2023, in connection with the expiration of its universal shelf registration statement on Form S-3 (File No. 333-250966) that was filed with the Securities and Exchange Commission (the “SEC”) on November 25, 2020 (the “2020 Registration Statement”), Microbot Medical Inc. (the “Company”) filed a new universal shelf registration statement on Form S-3 (File No. 333-275634) (the “2023 Registration Statement”), which was declared effective by the SEC on December 4, 2023. On July 1, 2024, the Company filed with the SEC a prospectus supplement relating to the Company’s “at the market offering” program (the “ATM Program”), which was previously registered under the 2020 Registration Statement. The prospectus supplement covers the offering of shares of the Company’s common stock under the ATM Program.

 

Sales of the shares of common stock under the ATM Program, if any, will be made by means of transactions that are deemed to be an “at the market offering” as defined in Rule 415 under the Securities Act of 1933, as amended, including sales made directly on or through the Nasdaq Capital Market, the existing trading market for our common stock, sales made to or through a market maker other than on an exchange or otherwise, directly to Wainwright as principal, in negotiated transactions at market prices prevailing at the time of sale or at prices related to such prevailing market prices, and/or in any other method permitted by law. The shares that may be sold under the ATM Program have an aggregate offering price of up to $4,819,905.

 

The Company previously entered into an At the Market Offering Agreement dated June 10, 2021, as amended on July 1, 2024 (the “Sales Agreement”), with H.C. Wainwright & Co., LLC in connection with the ATM Program. On July 1, 2024, the Company amended the Sales Agreement to, among other things, reflect that the shares of common stock issued under the ATM Program will be issued pursuant to the 2023 Registration Statement and the new prospectus supplement.

 

The foregoing description of the amendment to the Sales Agreement is not complete and is qualified in its entirety by reference to the full text of the amendment, which is filed as Exhibit 10.1 to this Current Report on Form 8-K and incorporated herein by reference.

 

The opinion of the Company’s counsel regarding the validity of the shares of common stock offered pursuant to the ATM Program under the new prospectus supplement is filed as Exhibit 5.1 to this Current Report on Form 8-K.

 

This Current Report on Form 8-K does not constitute an offer to sell or a solicitation of an offer to buy shares of the Company’s common stock, and there shall not be any sale of such shares in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. The sale of shares of the Company’s common stock is being made only by means of a prospectus and related prospectus supplement.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit No.    
5.1   Opinion of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.
10.1   Amendment to the At the Market Offering Agreement, dated July 1, 2024, by and between Microbot Medical Inc. and H.C. Wainwright & Co., LLC.
23.1   Consent of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. (contained in Exhibit 5.1).
104   Cover Page Interactive Data File (embedded within the XBRL document)

 

 
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  MICROBOT MEDICAL INC.
   
  By: /s/ Harel Gadot
  Name: Harel Gadot
  Title: Chief Executive Officer, President and Chairman

 

Dated: July 1, 2024

 

 

 

EX-5.1 2 ex5-1.htm

 

Exhibit 5.1

 

One Financial Center

Boston, MA 02111

(617) 542-6000

mintz.com

 

July 1, 2024

Microbot Medical Inc.

288 Grove Street, Suite 388

Braintree, MA 02184

Ladies and Gentlemen:

 

We have acted as counsel to Microbot Medical Inc., a Delaware corporation (the “Company”), in connection with the preparation and filing with the Securities and Exchange Commission (the “Commission”) of a Prospectus Supplement, dated July 1, 2024, to a Prospectus, dated December 4, 2023 (the “Prospectus and Prospectus Supplement”), filed pursuant to a Registration Statement on Form S-3, Registration No. 333-275634 (the “Registration Statement”), pursuant to which the Company is registering under the Securities Act of 1933, as amended (the “Securities Act”), the sale of up to $4,819,905 of shares (the “Placement Shares”) of common stock, $0.01 par value per share (the “Common Stock”), of the Company. The Placement Shares are being sold pursuant to a At the Market Offering Agreement, dated as of June 10, 2021, as amended on July 1, 2024, by and between the Company and H.C. Wainwright & Co., LLC (the “Agreement”), pursuant to which the Company may issue and sell the Placement Shares pursuant to the Registration Statement and the Prospectus and Prospectus Supplement.

 

In connection with this opinion, we have examined the Company’s Restated Certificate of Incorporation, as amended to date, and Amended and Restated By-laws, as amended to date, such other records of the corporate proceedings of the Company and certificates of the Company’s officers as we have deemed relevant, as well as the Registration Statement and the exhibits thereto and the Prospectus and the Prospectus Supplement.

 

In our examination, we have assumed the genuineness of all signatures, the legal capacity of natural persons, the authenticity of all documents submitted to us as originals, the conformity to original documents of all documents submitted to us as certified, photostatic or facsimile copies and the authenticity of the originals of such copies.

 

Based upon the foregoing, and subject to the limitations set forth below, we are of the opinion that the Placement Shares, when issued by the Company out of the Company’s duly authorized Common Stock and issued and delivered by the Company against payment therefor as contemplated by the Agreement, on terms approved by the Board of Directors of the Company, or a duly authorized committee thereof, will be duly and validly issued, fully paid and non-assessable.

 

Our opinion is limited to the General Corporation Law of the State of Delaware and the United States federal laws, and we express no opinion with respect to the laws of any other jurisdiction. No opinion is expressed herein with respect to the qualification of the Placement Shares under the securities or blue sky laws of any state or any foreign jurisdiction.

 

We have relied as to certain matters on information obtained from public officials, officers of the Company, and other sources believed by us to be responsible.

 

Please note that we are opining only as to the matters expressly set forth herein, and no opinion should be inferred as to any other matters. This opinion is based upon currently existing statutes, rules, regulations and judicial decisions, and we disclaim any obligation to advise you of any change in any of these sources of law or subsequent legal or factual developments which might affect any matters or opinions set forth herein.

 

We hereby consent to the filing of this opinion as an exhibit to a Current Report on Form 8-K and the Registration Statement in accordance with the requirements of Item 601(b)(5) of Regulation S-K under the Securities Act and to the use of this Firm’s name therein and in the Prospectus Supplement under the caption “Legal Matters.” In giving such consent, we do not hereby admit that we are in the category of persons whose consent is required under Section 7 of the Securities Act or the rules and regulations of the Commission.

 

  Very truly yours,
   
  /s/ Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.
  Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.

 

 

BOSTON LOS ANGELES MIAMI NEW YORK SAN DIEGO SAN FRANCISCO TORONTO WASHINGTON

MINTZ, LEVIN, COHN, FERRIS, GLOVSKY AND POPEO, P.C.

 

 

 

EX-10.1 3 ex10-1.htm

 

Exhibit 10.1

 

July 1, 2024

 

Microbot Medical Inc.

288 Grove Street, Suite 388

Braintree, MA 02184

Attention: Harel Gadot, President, CEO and Chairman

 

Dear Mr. Gadot:

 

Reference is made to the At The Market Offering Agreement, dated as of June 10, 2021 (the “ATM Agreement”), between Microbot Medical Inc. (the “Company”) and H.C. Wainwright & Co., LLC (“Wainwright”). This letter (the “Amendment”) constitutes an agreement between the Company and Wainwright to amend the ATM Agreement as set forth herein. Defined terms that are used but not defined herein shall have the meanings ascribed to such terms in the ATM Agreement.

 

1. The defined term “Agreement” in the ATM Agreement is amended to mean the ATM Agreement as amended by this Amendment.

 

2. The defined term “Registration Statement” in the ATM Agreement is amended by deleting “333-250966” and inserting in its place “333-275634”.

 

3. The first sentence of Section 2(b)(vii) of the ATM Agreement is hereby amended and restated in its entirety as follows:

 

“Unless otherwise agreed between the Company and the Manager, settlement for sales of the Shares will occur at 10:00 a.m. (New York City time) on the first (1st) Trading Day (or any such shorter settlement cycle as may be in effect pursuant to Rule 15c6-1 under the Exchange Act from time to time) following the date on which such sales are made (each, a “Settlement Date”).”

 

1
 

 

4. Section 3(g) of the ATM Agreement is hereby amended and restated in its entirety as follows:

 

Capitalization. The capitalization of the Company is as set forth in the SEC Reports as of the date set forth therein. The Company has not issued any capital stock since its most recently filed SEC Report under the Exchange Act (or in respect of issuances following the date hereof, as set forth in its most recently filed periodic report under the Exchange Act or in a Form 8-K), other than pursuant to the exercise of employee stock options under the Company’s or Subsidiaries’ equity incentive, performance, stock option or compensatory plan, contract or arrangement (a “Plan”), the issuance of shares of Common Stock to employees pursuant to the Company’s employee stock purchase plans and pursuant to the conversion and/or exercise of securities exercisable, exchangeable or convertible into Common Stock (“Common Stock Equivalents”) outstanding as of the date of the most recently filed periodic report under the Exchange Act. No Person has any right of first refusal, preemptive right, right of participation, or any similar right to participate in the transactions contemplated by this Agreement. Except as set forth in the SEC Reports, there are no outstanding options, warrants, scrip rights to subscribe to, calls or commitments of any character whatsoever relating to, or securities, rights or obligations convertible into or exercisable or exchangeable for, or giving any Person any right to subscribe for or acquire, any shares of Common Stock or the capital stock of any Subsidiary, or contracts, commitments, understandings or arrangements by which the Company or any Subsidiary is or may become bound to issue additional shares of Common Stock or Common Stock Equivalents or capital stock of any Subsidiary. The issuance and sale of the Shares will not obligate the Company or any Subsidiary to issue shares of Common Stock or other securities to any Person. Except as set forth in the SEC Reports, there are no outstanding securities or instruments of the Company or any Subsidiary with any provision that adjusts the exercise, conversion, exchange or reset price of such security or instrument upon an issuance of securities by the Company or any Subsidiary. Except as set forth in the SEC Reports, there are no outstanding securities or instruments of the Company or any Subsidiary that contain any redemption or similar provisions, and there are no contracts, commitments, understandings or arrangements by which the Company or any Subsidiary is or may become bound to redeem a security of the Company or such Subsidiary. Except as disclosed in the SEC Reports, the Company does not have any stock appreciation rights or “phantom stock” plans or agreements or any similar plan or agreement. All of the outstanding shares of capital stock of the Company are duly authorized, validly issued, fully paid and nonassessable, have been issued in compliance with all federal and state securities laws, and none of such outstanding shares was issued in violation of any preemptive rights or similar rights to subscribe for or purchase securities. There are no stockholders agreements, voting agreements or other similar agreements with respect to the Company’s capital stock to which the Company is a party or, to the knowledge of the Company, between or among any of the Company’s stockholders.”

 

5. The last sentence of Section 3(h) of the ATM Agreement is hereby amended and restated in its entirety as follows:

 

“The Company meets the transaction requirements as set forth in General Instruction I.B.1 of Form S-3 or, if applicable, as set forth in General Instruction I.B.6 of Form S-3 with respect to the aggregate market value of securities being sold pursuant to this offering and during the twelve (12) months prior to such time that this representation is repeated or deemed to be made.”

 

6. The second sentence of Section 3(v) of the ATM Agreement is hereby amended and restated in its entirety as follows:

 

“None of, and neither the Company nor any Subsidiary has received a notice (written or otherwise) that any of, the Intellectual Property Rights has expired, terminated or been abandoned, or is expected to expire or terminate or be abandoned, within two (2) years from the date of this Agreement, except as would not be reasonably expected to have a Material Adverse Effect or as disclosed in the SEC Reports.”

 

2
 

 

7. Section 3(bb) of the ATM Agreement is hereby amended and restated in its entirety as follows:

 

Investment Company. The Company is not, and is not an Affiliate of, and immediately after receipt of payment for the Shares from the Manager pursuant to this Agreement, will not be or be an Affiliate of, an “investment company” within the meaning of the Investment Company Act of 1940, as amended. The Company shall conduct its business in a manner so that it will not become an “investment company” subject to registration under the Investment Company Act of 1940, as amended. The Company shall conduct its business in a manner so as to reasonably ensure that it or its Subsidiaries will not become an “investment company” subject to registration under the Investment Company Act of 1940, as amended.”

 

8. A new Section 3(qq) of the ATM Agreement is inserted and reads as follows:

 

Cybersecurity. (i)(x) There has been no security breach or other compromise of or relating to any of the Company’s or any Subsidiary’s information technology and computer systems, networks, hardware, software, data (including the data of its respective customers, employees, suppliers, vendors and any third party data maintained by or on behalf of it), equipment or technology (collectively, “IT Systems and Data”) and (y) the Company and the Subsidiaries have not been notified of, and has no knowledge of any event or condition that would reasonably be expected to result in, any security breach or other compromise to its IT Systems and Data; (ii) the Company and the Subsidiaries are presently in compliance with all applicable laws or statutes and all judgments, orders, rules and regulations of any court or arbitrator or governmental or regulatory authority, internal policies and contractual obligations relating to the privacy and security of IT Systems and Data and to the protection of such IT Systems and Data from unauthorized use, access, misappropriation or modification, except as would not, individually or in the aggregate, have a Material Adverse Effect; (iii) the Company and the Subsidiaries have implemented and maintained commercially reasonable safeguards to maintain and protect its material confidential information and the integrity, continuous operation, redundancy and security of all IT Systems and Data; and (iv) the Company and the Subsidiaries have implemented backup and disaster recovery technology consistent with industry standards and practices.”

 

3
 

 

9. A new Section 3(rr) of the ATM Agreement is inserted and reads as follows:

 

Compliance with Data Privacy Laws. (i) The Company and the Subsidiaries are, and at all times during the past three years were, in compliance with all applicable data privacy and security laws and regulations, including, as applicable, the European Union General Data Protection Regulation (“GDPR”) (EU 2016/679) (collectively, “Privacy Laws”); (ii) the Company and the Subsidiaries have in place, comply with, and take appropriate steps reasonably designed to ensure compliance with their policies and procedures relating to data privacy and security and the collection, storage, use, disclosure, handling and analysis of Personal Data (the “Policies”); (iii) the Company provides accurate notice of its applicable Policies to its customers, employees, third party vendors and representatives as required by Privacy Laws; and (iv) applicable Policies provide accurate and sufficient notice of the Company’s then-current privacy practices relating to its subject matter, and do not contain any material omissions of the Company’s then-current privacy practices, as required by Privacy Laws. “Personal Data” means (i) a natural person’s name, street address, telephone number, email address, photograph, social security number, bank information, or customer or account number; (ii) any information which would qualify as “personally identifying information” under the Federal Trade Commission Act, as amended; (iii) “personal data” as defined by GDPR; and (iv) any other piece of information that allows the identification of such natural person, or his or her family, or permits the collection or analysis of any identifiable data related to an identified person’s health or sexual orientation. (i) None of such disclosures made or contained in any of the Policies have been inaccurate, misleading, or deceptive in violation of any Privacy Laws and (ii) the execution, delivery and performance of this Agreement will not result in a breach of any Privacy Laws or Policies. Neither the Company nor the Subsidiaries, (i) has, to the knowledge of the Company, received written notice of any actual or potential liability of the Company or the Subsidiaries under, or actual or potential violation by the Company or the Subsidiaries of, any of the Privacy Laws; (ii) is currently conducting or paying for, in whole or in part, any investigation, remediation or other corrective action pursuant to any regulatory request or demand pursuant to any Privacy Law; or (iii) is a party to any order, decree, or agreement by or with any court or arbitrator or governmental or regulatory authority that imposed any obligation or liability under any Privacy Law.”

 

10. Section 4(l) of the ATM Agreement is hereby amended and restated in its entirety as follows:

 

Bring Down Opinions; Negative Assurance. Unless waived by the Manager, the Company shall furnish or cause to be furnished forthwith to the Manager and to counsel to the Manager a written opinion of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. (“Mintz”) addressed to the Manager and dated and delivered on such date, in form and substance reasonably satisfactory to the Manager and a negative assurance representation from Ruskin Moscou Faltischek, P.C. (“Ruskin”) addressed to the Manager and dated and delivered on such date, in form and substance reasonably satisfactory to the Manager, at each Representation Date; provided, however, that the requirement for the Company to furnish or cause to be furnished an opinion (but not with respect to a negative assurance representation) under this Section 4(l) shall be waived for any Representation Date other than a Representation Date on which a material amendment to the Registration Statement or Prospectus is made or on which the Company files its Annual Report on Form 10-K or a material amendment thereto under the Exchange Act, unless the Manager reasonably requests, upon a material adverse change in the results of operations, business or condition of the Company, such opinion required by this Section 4(l) in connection with a Representation Date, upon which request such opinion shall be deliverable hereunder. The Manager hereby agrees that each of Mintz and Ruskin may provide a reliance letter for a previously delivered opinion or negative assurance representation, as applicable, stating that such opinion or negative assurance representation may continue to be relied on, in lieu of providing an opinion or negative assurance representation on any such date.”

 

4
 

 

11. Section 4(l) of the ATM Agreement is hereby amended and restated in its entirety as follows:

 

“Delivery of Opinion. The Company shall have caused (i) Mintz to furnish its opinion to the Manager and (ii) Ruskin to furnish its negative assurance statement to the Manager, each dated as of such date and addressed to the Manager in form and substance acceptable to the Manager.”

 

12. Section 7(a) of the ATM Agreement is hereby amended and restated in its entirety as follows:

 

(a)Indemnification by Company. The Company agrees to indemnify and hold harmless the Manager, the directors, officers, employees and agents of the Manager and each person who controls the Manager within the meaning of either the Act or the Exchange Act against any and all losses, claims, damages or liabilities, joint or several, to which they or any of them may become subject under the Act, the Exchange Act or other Federal or state statutory law or regulation, at common law or otherwise, insofar as such losses, claims, damages or liabilities (or actions in respect thereof) arise out of or are based upon any untrue statement or alleged untrue statement of a material fact contained in the Registration Statement for the registration of the Shares as originally filed or in any amendment thereof, or in the Base Prospectus, any Prospectus Supplement, the Prospectus, any Issuer Free Writing Prospectus, or in any amendment thereof or supplement thereto, or arise out of or are based upon the omission or alleged omission to state therein a material fact required to be stated therein or necessary to make the statements therein not misleading or arise out of or are based upon any Proceeding, commenced or threatened (whether or not the Manager is a target of or party to such Proceeding) or result from or relate to any breach of any of the representations, warranties, covenants or agreements made by the Company in this Agreement, and agrees to reimburse each such indemnified party for any legal or other expenses reasonably incurred by them in connection with investigating or defending any such loss, claim, damage, liability or action; provided, however, that the Company will not be liable in any such case to the extent that any such loss, claim, damage or liability arises out of or is based upon any such untrue statement or alleged untrue statement or omission or alleged omission made therein in reliance upon and in conformity with written information furnished to the Company by the Manager specifically for inclusion therein. This indemnity agreement will be in addition to any liability that the Company may otherwise have.”

 

5
 

 

13. The second sentence of Section 13 of the ATM Agreement is hereby amended and restated as follows:

 

“Notwithstanding anything herein to the contrary, this Agreement shall not supersede the letter agreement, dated May 29, 2024, by and between the Company and the Manager, which shall, to the extent it remains effective in accordance with the terms thereof, continue to survive and be enforceable by the Manager in accordance with its terms, provided that, in the event of a conflict between the terms of the letter agreement and this Agreement, the terms of this Agreement shall prevail.”

 

14. The Company and Wainwright hereby agree that the date hereof shall be a Representation Date under the ATM Agreement and the Company shall file a Prospectus Supplement with the Commission on the date hereof and deliver the deliverables pursuant to Sections 4(k), 4(l) and 4(m) of the ATM Agreement on the date hereof and shall reimburse Wainwright for legal fees and expenses in the amount of $50,000 on the date hereof.

 

15. Except as expressly set forth herein, all of the terms and conditions of the ATM Agreement shall continue in full force and effect after the execution of this Amendment and shall not be in any way be changed, modified or superseded by the terms set forth herein.

 

16. This Amendment may be executed in two or more counterparts and by facsimile or “.pdf” signature or otherwise, and each of such counterparts shall be deemed an original and all of such counterparts together shall constitute one and the same agreement. Counterparts may be delivered via electronic mail (including any electronic signature covered by the U.S. federal ESIGN Act of 2000, Uniform Electronic Transactions Act, the Electronic Signatures and Records Act or other applicable law, e.g., www.docusign.com) or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes.

 

[remainder of page intentionally left blank]

 

6
 

 

In acknowledgment that the foregoing correctly sets forth the understanding reached by the Company and Wainwright, please sign in the space provided below, whereupon this Amendment shall constitute a binding amendment to the ATM Agreement as of the date indicated above.

 

  Very truly yours,
     
  H.C. WAINWRIGHT & CO., LLC
                      
  By: /s/ Edward D. Silvera
  Name:

Edward D. Silvera

  Title:

Chief Operating Officer

 

Accepted and Agreed:

 

Microbot Medical Inc.  
     
By:

/s/ Harel Gadot

 
Name: Harel Gadot  
Title:

Chief Executive Officer, President and Chairman

 

 

[signature page to MBOT Amendment to atm agreement]

 

7

 

GRAPHIC 4 ex5-1_001.jpg begin 644 ex5-1_001.jpg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end EX-101.SCH 5 mbot-20240701.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 6 mbot-20240701_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 7 mbot-20240701_pre.xml XBRL PRESENTATION FILE XML 9 R1.htm IDEA: XBRL DOCUMENT v3.24.2
Cover
Jul. 01, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jul. 01, 2024
Entity File Number 000-19871
Entity Registrant Name MICROBOT MEDICAL INC.
Entity Central Index Key 0000883975
Entity Tax Identification Number 94-3078125
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 288 Grove Street
Entity Address, Address Line Two Suite 388
Entity Address, City or Town Braintree
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02184
City Area Code (781)
Local Phone Number 875-3605
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $0.01 par value
Trading Symbol MBOT
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 14 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.2 html 1 23 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://microbotmedical.com/role/Cover Cover Cover 1 false false All Reports Book All Reports form8-k.htm mbot-20240701.xsd mbot-20240701_lab.xml mbot-20240701_pre.xml http://xbrl.sec.gov/dei/2024 true false JSON 16 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "form8-k.htm": { "nsprefix": "MBOT", "nsuri": "http://microbotmedical.com/20240701", "dts": { "inline": { "local": [ "form8-k.htm" ] }, "schema": { "local": [ "mbot-20240701.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd" ] }, "labelLink": { "local": [ "mbot-20240701_lab.xml" ] }, "presentationLink": { "local": [ "mbot-20240701_pre.xml" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2024": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2024": 23 }, "report": { "R1": { "role": "http://microbotmedical.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2024-07-01", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form8-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-07-01", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form8-k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentDescription", "presentation": [ "http://microbotmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": [ "http://microbotmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AnnualInformationForm", "presentation": [ "http://microbotmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://microbotmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": [ "http://microbotmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CountryRegion", "presentation": [ "http://microbotmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://microbotmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentAccountingStandard", "presentation": [ "http://microbotmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentAnnualReport", "presentation": [ "http://microbotmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://microbotmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://microbotmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": [ "http://microbotmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodStartDate", "presentation": [ "http://microbotmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": [ "http://microbotmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentRegistrationStatement", "presentation": [ "http://microbotmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://microbotmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentShellCompanyReport", "presentation": [ "http://microbotmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": [ "http://microbotmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": [ "http://microbotmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://microbotmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": [ "http://microbotmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine2", "presentation": [ "http://microbotmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine3", "presentation": [ "http://microbotmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": [ "http://microbotmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCountry", "presentation": [ "http://microbotmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://microbotmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://microbotmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://microbotmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": [ "http://microbotmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://microbotmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://microbotmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://microbotmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityExTransitionPeriod", "presentation": [ "http://microbotmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": [ "http://microbotmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": [ "http://microbotmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://microbotmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://microbotmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityPrimarySicNumber", "presentation": [ "http://microbotmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://microbotmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": [ "http://microbotmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": [ "http://microbotmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": [ "http://microbotmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://microbotmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityVoluntaryFilers", "presentation": [ "http://microbotmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://microbotmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Extension", "presentation": [ "http://microbotmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": [ "http://microbotmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "NoTradingSymbolFlag", "presentation": [ "http://microbotmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://microbotmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://microbotmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementTenderOffer", "presentation": [ "http://microbotmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": [ "http://microbotmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12gTitle", "presentation": [ "http://microbotmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": [ "http://microbotmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityReportingObligation", "presentation": [ "http://microbotmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SolicitingMaterial", "presentation": [ "http://microbotmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": [ "http://microbotmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "WrittenCommunications", "presentation": [ "http://microbotmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14a", "Subsection": "12" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 17 0001493152-24-025813-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-24-025813-xbrl.zip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end XML 18 form8-k_htm.xml IDEA: XBRL DOCUMENT 0000883975 2024-07-01 2024-07-01 iso4217:USD shares iso4217:USD shares false 0000883975 8-K 2024-07-01 MICROBOT MEDICAL INC. DE 000-19871 94-3078125 288 Grove Street Suite 388 Braintree MA 02184 (781) 875-3605 false false false false Common Stock, $0.01 par value MBOT NASDAQ false